Nordic investment company, Impilo, and sector investor, SHS, have acquired Lowenco A/S, an ultra-low temperature manufacturer. Lowenco has been acquired from investment banking and financial advisory firm, Brown Gibbons Lang & Co.
Impilo is focused on long-term investments in health-related areas such as pharmaceuticals, medical technology and healthcare services. It is currently investing from its fifth fund, which was launched in 2018.
BGL’s healthcare & life sciences team advises companies across the diagnostics, research tools, lab equipment and device landscape. It provides capital formation, technology strategy, corporate ventures, and medical device M&A strategy to its clients. BGL also closely follows regulatory and reimbursement trends, helping to maintain active relationships with global industry participants and capital providers.
Lowenco’s storage services are used across the pharmaceutical and biotech industries. The company’s modular and large-scale services have been developed under the brand names LSSU and CON20, and are delivered wherever GMP guidelines are followed. Following the transaction, Lowenco’s management team will remain and continue to be led by CEO Mikael Hoier.